- Home
- ANL vs SOPH Comparison
ANL vs SOPH Comparison
Compare ANL & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | SOPH |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Cayman Islands | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 367.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANL | SOPH |
|---|---|---|
| Price | $15.68 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $7.00 |
| AVG Volume (30 Days) | ★ 350.7K | 84.7K |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $2.58 |
| 52 Week High | $13.00 | $5.70 |
Technical Indicators
Market Signals| Indicator | ANL | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 80.26 | 56.70 |
| Support Level | $1.36 | $4.54 |
| Resistance Level | N/A | $5.30 |
| Average True Range (ATR) | 1.38 | 0.30 |
| MACD | 0.70 | -0.00 |
| Stochastic Oscillator | 99.31 | 63.01 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.